On January 4, 2018, Genetron Health Beijing Co. Ltd. announced its completion of financing of round C of over 400 million RMB. This round of funding was led by CICC Kangrui Healthcare Private Equity Fund I, L.P., and followed by several other institutions.
Since its founding, Genetron Health has built a highly professional, multidisciplinary and experienced team of experts with four years of devotion, and continued to improve its testing services and in-vitro diagnostic products covering the full cycle of cancer and multiple cancers. It has established two R & D centers in North Carolina (US) and Beijing (China), and four clinical laboratories covering over 10,000 square meters in major areas across China. It runs the business covering hundreds of domestic and foreign research institutions and clinical hospitals, and has already carried forward a complete layout which covers both the upstream and downstream of the industry chain in an in-depth manner.
This round of funding will be used for technology R & D, product line expansion, market education, and accumulation of big data, etc., with its focus on promoting the application of liquid biopsy technology in cancer diagnosis and early detection.